CMT Association, Applied Team Up on Therapy for New Subtype

CMT Association, Applied Team Up on Therapy for New Subtype

310415

CMT Association, Applied Team Up on Therapy for New Subtype

A new partnership is seeking to identify people with a mutation in the sorbitol dehydrogenase (SORD) gene — the cause of a newly identified type of Charcot-Marie-Tooth disease (CMT) — who may be eligible for clinical trials investigating potential treatments for this recessive subtype. In this collaboration, the Charcot–Marie–Tooth Association (CMTA) and Applied Therapeutics, a clinical-stage biopharmaceutical company, will seek people with SORD mutations who may be interested in participating in future clinical trials through the…

You must be logged in to read/download the full post.